American pharmaceutical company, AbbVie, has unveiled plans to invest $1.4bn in a new pharmaceutical manufacturing campus in Durham, marking a significant expansion of its U.S. production footprint and a major boost for the state’s life sciences sector.
The 185-acre site, located near Research Triangle Park, will integrate advanced manufacturing technologies, next-generation laboratories and artificial intelligence (AI) to support production of medicines across immunology, neuroscience and oncology.
Construction is set to begin this year, with the campus expected to be fully operational by the end of 2028.
Jobs and regional impact
AbbVie’s investment is expected to deliver a substantial economic uplift, with the company planning to create 734 permanent roles over the next four years. These positions will span engineering, scientific research, manufacturing operations and laboratory work.
In addition, the build-out phase will generate more than 2,000 construction jobs, reinforcing the project’s near-term economic impact alongside its long-term employment prospects.
“Our investment in North Carolina represents a significant milestone for AbbVie as our largest capital investment to date and an important expansion of our manufacturing footprint into a new region of the United States.”
– Robert A. Michael, Chairman and CEO of AbbVie.
Building on wider U.S. expansion
The Durham campus forms part of AbbVie’s broader $100bn commitment to U.S. R&D and capital investment over the next decade, and follows a steady cadence of domestic manufacturing announcements.
Earlier this year, the company revealed a $380m investment in new active pharmaceutical ingredient (API) manufacturing facilities in North Chicago, aimed at expanding capacity for next-generation neuroscience and obesity treatments. That project, which will create around 300 jobs, highlights AbbVie’s parallel focus on strengthening both drug substance (API) and drug product manufacturing in the U.S.
Together, the investments signal a coordinated strategy to build end-to-end domestic capability—improving supply chain resilience while accelerating the adoption of advanced manufacturing and AI-driven processes.
Strengthening U.S. manufacturing capacity
The first phase of the Durham development will include facilities dedicated to small volume parenteral (SVP) drug production—sterile injectable medicines typically delivered via vials, prefilled syringes or cartridges—as well as laboratories, warehousing, office space and employee wellness amenities.
Once complete, the site is expected to become AbbVie’s U.S. centre of excellence for SVP manufacturing, supplying next-generation medicines to both domestic and global markets.
North Carolina’s life sciences appeal
State leaders have highlighted the decision as further validation of North Carolina’s position as a leading U.S. life sciences hub.
“When you combine our world-renowned research and innovation with a strong, thriving life sciences hub, North Carolina quickly becomes the premier location for biopharmaceutical companies to do business.”
– Josh Stein, Governor of North Carolina.
The investment reinforces the pull of the Research Triangle region, where a combination of skilled talent, academic partnerships and established biotech infrastructure continues to attract major industry players.
Interested in receiving the latest North American manufacturing news in your inbox each week?
Sign up to The Manufacturer Digital Briefing – North American Edition